|
Alan B. Colowick, M.D., M.P.H., has been the President of Geron Oncology since October 2006. From January 2005 until joining Geron, Dr. Colowick was the Chief Medical Officer of Threshold Pharmaceuticals Inc., where he was responsible for all aspects of non-clinical and clinical development and manufacturing. From 1999 to 2005, Dr. Colowick held various management positions with Amgen, Inc., most recently serving as vice president of European Medical Affairs, where he was responsible for products in multiple therapeutic areas, including hematology/oncology, nephrology and internal medicine. From 1996 to 1999, Dr. Colowick was a clinical and research fellow in hematology-oncology at Harvard University and the Brigham and Women�s Hospital/Dana Farber Cancer Institute. Dr. Colowick holds a B.S. in Molecular Biology from the University of Colorado, a M.D. from Stanford University and a M.P.H from Harvard University. | 